CoChat
Sign Up
Cited by 26Schizophrenia research and treatmentMental Health and PsychiatryHallucinations in medical conditions

A Rating Scale for Psychotic Symptoms (RSPS)

Chouinard, Guy, Miller, Robert·1999·Schizophrenia Research
DOI 10.1016/s0920-9964(99)00012-2
Open this paper in CoChat — free account

Abstract

The authors present a new rating scale for the psychotic symptoms of schizophrenia and related psychoses. The scale links specific symptoms of psychopathology to dysfunction and overactivity of dopaminergic mechanisms underlying the processes of reward and selective attention. The Rating Scale for Psychotic Symptoms (RSPS) is a 44-item rating instrument with a seven-point severity scale for each item. Psychotic symptoms are classified into three groups: Pathological amplification of mental images (perception symptoms) (subscale 1), Distraction symptoms (including catatonia and passivity experiences) (subscale 2), and Delusions (subscale 3). A dimensional, rather than a categorical, conceptualization of psychosis is assumed. Rating is accomplished through a manual and a semi-structured interview (SSCI-RSPS). In this first of two papers, general issues about the construction of the scale and the derivation of symptom groups are discussed. Dopamine-mediated modification of cortico-striatal synapses is seen as being of critical importance in all three groups of symptoms. In this first paper, we present subscale I (perception symptoms), which includes both amplified perceptual images (illusions) and hallucinations. A total of seven illusions and 11 hallucinations are rated as individual items.

Integrity signals

Registry

Crossref · 10.1016/s0920-9964(99)00012-2

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a group cognitive-behavioral therapy aimed at relapse prevention for patients tapering antidepressants within 4 months, only 37% (n = 26) succeeded in discontinuing the drug and only 28% (n = 20) succeeded in discontinuing without recurrence.

    “Regarding non-pharmacological interventions, when a group cognitive-behavioral therapy aimed at relapse prevention was proposed to patients who were tapering antidepressants within 4 months according to a fixed schedule, only 37% ( n = 26) of the subjects succeeded in discontinuing the drug and only 28% ( n = 20) succeeded in discontinuing without recurrence.”

    From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [133]

  • The results of the group cognitive-behavioral therapy trial might be partly due to the vulnerability of the sample under study, the majority of whom had unsuccessfully tried to discontinue before.

    “as well as to the vulnerability of the sample under study, the majority had unsuccessfully tried to discontinue before [133].”

    From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [133]

Cites

Flagged first, then by citations

2 of the 66 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Chouinard, G., & Miller, R.
Affiliations
  • Institut universitaire en santé mentale de Montréal (CA)
  • University of Otago (NZ)
Corresponding author
Chouinard, Guy
ORCID
Miller, Robert
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
1999-08
Volume
38
Issue
2-3
Pages
101-122
ISSN
0920-9964 (ISSN-L)
DOI
10.1016/s0920-9964(99)00012-2
OpenAlex
W2160157920
Cited by
26
References
66
Citations by year
2025: 1 · 2022: 1 · 2020: 3 · 2019: 1 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 1 · 2012: 1
FWCI
0.48
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Health Research Council of New Zealand
  • Division of Information Systems
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Keywords
psychotic symptoms
MeSH terms
Behavioral Symptoms, Brain, Cerebral Cortex, Corpus Striatum, Dopamine, Humans, Interview, Psychological, Models, Psychological, Neural Pathways, Neuropsychological Tests, Perceptual Disorders, Perceptual Distortion, Psychiatric Status Rating Scales, Psychometrics, Psychotic Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review